Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Biohaven Sets Up China Subsidiary for Migraine/CNS Drugs

publication date: Nov 30, 2018

US-Based Biohaven Pharma formed a Shanghai subsidiary, BioShin™, to develop and commercialize its late-stage migraine and neurology portfolio in China and other Asia-Pacific markets. To build its portfolio, Biohaven has combined internal R&D with in-licensings from biopharmas and institutions. Earlier this week, the company filed a US NDA for a sublingual formulation of the ALS drug riluzole as a treatment for migraine. More details....

Stock Symbol: (NSDQ: BHVN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.